ES2630002T5 - Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa - Google Patents
Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa Download PDFInfo
- Publication number
- ES2630002T5 ES2630002T5 ES06712292T ES06712292T ES2630002T5 ES 2630002 T5 ES2630002 T5 ES 2630002T5 ES 06712292 T ES06712292 T ES 06712292T ES 06712292 T ES06712292 T ES 06712292T ES 2630002 T5 ES2630002 T5 ES 2630002T5
- Authority
- ES
- Spain
- Prior art keywords
- cancer
- dose
- ftd
- therapeutic drug
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/042,059 US7799783B2 (en) | 2005-01-26 | 2005-01-26 | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| US42059 | 2005-01-26 | ||
| JP2005165156 | 2005-06-06 | ||
| JP2005165156 | 2005-06-06 | ||
| PCT/JP2006/301097 WO2006080327A1 (ja) | 2005-01-26 | 2006-01-25 | α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2630002T3 ES2630002T3 (es) | 2017-08-17 |
| ES2630002T5 true ES2630002T5 (es) | 2024-09-19 |
Family
ID=36740357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06712292T Active ES2630002T5 (es) | 2005-01-26 | 2006-01-25 | Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1849470B2 (Direct) |
| JP (1) | JP5576591B2 (Direct) |
| KR (1) | KR101468216B1 (Direct) |
| AU (1) | AU2006209547C1 (Direct) |
| BE (1) | BE2017C028I2 (Direct) |
| CA (1) | CA2594713A1 (Direct) |
| CY (2) | CY2017029I2 (Direct) |
| DK (1) | DK1849470T4 (Direct) |
| ES (1) | ES2630002T5 (Direct) |
| FI (1) | FI1849470T4 (Direct) |
| FR (1) | FR17C1028I2 (Direct) |
| HU (2) | HUE033306T2 (Direct) |
| LT (2) | LT1849470T (Direct) |
| LU (1) | LUC00036I2 (Direct) |
| NL (1) | NL300889I2 (Direct) |
| PL (1) | PL1849470T5 (Direct) |
| PT (1) | PT1849470T (Direct) |
| RU (1) | RU2394581C2 (Direct) |
| SI (1) | SI1849470T2 (Direct) |
| TW (1) | TWI362265B (Direct) |
| WO (1) | WO2006080327A1 (Direct) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| CA2594713A1 (en) | 2005-01-26 | 2006-08-03 | Taiho Pharmaceutical Co., Ltd. | Anticancer drug containing .alpha.,.alpha.,.alpha.-trifluorothymidine and thymidine phosphorylase inhibitor |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| ES2587381T3 (es) * | 2007-04-25 | 2016-10-24 | Cyclacel Limited | Uso de sapacitabina para tratar una enfermedad proliferativa |
| EP2249811A1 (en) | 2008-01-25 | 2010-11-17 | Grünenthal GmbH | Pharmaceutical dosage form |
| CA2723438C (en) | 2008-05-09 | 2016-10-11 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
| WO2009138507A2 (en) * | 2008-05-15 | 2009-11-19 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Anti-cancer combination therapy |
| CN102573805A (zh) | 2009-07-22 | 2012-07-11 | 格吕伦塔尔有限公司 | 热熔挤出的控制释放剂型 |
| WO2011009603A1 (en) | 2009-07-22 | 2011-01-27 | Grünenthal GmbH | Tamper-resistant dosage form for oxidation-sensitive oploids |
| BR112013005194A2 (pt) | 2010-09-02 | 2016-05-03 | Gruenenthal Gmbh | forma de dosagem resistente à violação compreendendo sal inorgânico |
| ES2487244T3 (es) | 2010-09-02 | 2014-08-20 | Grünenthal GmbH | Forma de dosificación resistente a la manipulación que comprende un polímero aniónico |
| HRP20171458T1 (hr) | 2011-07-29 | 2017-11-17 | Grünenthal GmbH | Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka |
| PE20141638A1 (es) | 2011-07-29 | 2014-11-22 | Gruenenthal Chemie | Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato |
| HUE035347T2 (en) | 2011-08-16 | 2018-05-02 | Taiho Pharmaceutical Co Ltd | Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer |
| TWI503122B (zh) | 2012-02-15 | 2015-10-11 | Taiho Pharmaceutical Co Ltd | Oral administration of pharmaceutical compositions |
| TWI526210B (zh) * | 2012-02-15 | 2016-03-21 | Taiho Pharmaceutical Co Ltd | Oral pharmaceutical composition |
| BR112014019988A8 (pt) | 2012-02-28 | 2017-07-11 | Gruenenthal Gmbh | Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico |
| WO2013137284A1 (ja) | 2012-03-14 | 2013-09-19 | 日清ファルマ株式会社 | 含硫アミノ酸含有組成物 |
| SI2838512T1 (sl) | 2012-04-18 | 2018-11-30 | Gruenenthal Gmbh | Pred posegi in prehitrim sproščanjem odporna farmacevtska oblika odmerka |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| NZ700924A (en) | 2012-05-16 | 2016-02-26 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
| RS60958B1 (sr) * | 2013-03-27 | 2020-11-30 | Taiho Pharmaceutical Co Ltd | Antitumorski agens koji uključuje irinotekan hidrohlorid hidrat |
| SMT201800677T1 (it) | 2013-03-27 | 2019-01-11 | Taiho Pharmaceutical Co Ltd | Agente antitumorale includente irinotecano cloridrato idrato a basso dosaggio |
| TWI595879B (zh) | 2013-05-17 | 2017-08-21 | 大鵬藥品工業股份有限公司 | Prediction of therapeutic effect in patients with colorectal cancer with TK1 protein hyperactivity |
| EP3003279A1 (en) | 2013-05-29 | 2016-04-13 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
| WO2014191396A1 (en) | 2013-05-29 | 2014-12-04 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| EA032465B1 (ru) | 2013-07-12 | 2019-05-31 | Грюненталь Гмбх | Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления |
| RS64243B1 (sr) | 2013-09-06 | 2023-06-30 | Taiho Pharmaceutical Co Ltd | Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta |
| EP3073994A1 (en) | 2013-11-26 | 2016-10-05 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| EA201692388A1 (ru) | 2014-05-26 | 2017-05-31 | Грюненталь Гмбх | Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы |
| AU2016251854A1 (en) | 2015-04-24 | 2017-10-19 | Grunenthal Gmbh | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| AU2016319203A1 (en) | 2015-09-10 | 2018-02-22 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| KR102281961B1 (ko) * | 2016-01-08 | 2021-07-26 | 다이호야쿠힌고교 가부시키가이샤 | 면역 조절제를 함유하는 항종양제 및 항종양 효과 증강제 |
| WO2017135412A1 (ja) * | 2016-02-05 | 2017-08-10 | 大鵬薬品工業株式会社 | 重度腎機能障害を有する癌患者に対する治療方法 |
| US10866219B2 (en) | 2017-12-22 | 2020-12-15 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine- and/or tipiracil-related substance |
| EP3730935A4 (en) | 2017-12-22 | 2022-02-23 | Taiho Pharmaceutical Co., Ltd. | METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL |
| US10816517B2 (en) | 2018-01-05 | 2020-10-27 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine-related substance by high-performance liquid chromatography |
| WO2019135405A1 (ja) | 2018-01-05 | 2019-07-11 | 大鵬薬品工業株式会社 | トリフルリジン由来の類縁物質の検出方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE245631T1 (de) * | 1995-03-29 | 2003-08-15 | Taiho Pharmaceutical Co Ltd | Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel |
| CA2238331C (en) * | 1996-09-24 | 2003-02-25 | Taiho Pharmaceutical Co., Ltd. | Cancerous metastasis inhibitors containing uracil derivatives |
| CA2594713A1 (en) | 2005-01-26 | 2006-08-03 | Taiho Pharmaceutical Co., Ltd. | Anticancer drug containing .alpha.,.alpha.,.alpha.-trifluorothymidine and thymidine phosphorylase inhibitor |
-
2006
- 2006-01-25 CA CA002594713A patent/CA2594713A1/en not_active Withdrawn
- 2006-01-25 PT PT67122929T patent/PT1849470T/pt unknown
- 2006-01-25 JP JP2007500529A patent/JP5576591B2/ja active Active
- 2006-01-25 RU RU2007132181/15A patent/RU2394581C2/ru active
- 2006-01-25 AU AU2006209547A patent/AU2006209547C1/en active Active
- 2006-01-25 DK DK06712292.9T patent/DK1849470T4/da active
- 2006-01-25 ES ES06712292T patent/ES2630002T5/es active Active
- 2006-01-25 WO PCT/JP2006/301097 patent/WO2006080327A1/ja not_active Ceased
- 2006-01-25 SI SI200632192T patent/SI1849470T2/sl unknown
- 2006-01-25 EP EP06712292.9A patent/EP1849470B2/en active Active
- 2006-01-25 PL PL06712292.9T patent/PL1849470T5/pl unknown
- 2006-01-25 LT LTEP06712292.9T patent/LT1849470T/lt unknown
- 2006-01-25 HU HUE06712292A patent/HUE033306T2/hu unknown
- 2006-01-26 TW TW095103114A patent/TWI362265B/zh active
-
2007
- 2007-07-19 KR KR1020077016492A patent/KR101468216B1/ko active Active
-
2017
- 2017-07-28 LT LTPA2017024 patent/LTC1849470I2/lt unknown
- 2017-08-01 HU HUS1700032C patent/HUS1700032I1/hu unknown
- 2017-08-03 BE BE2017C028C patent/BE2017C028I2/fr unknown
- 2017-08-08 NL NL300889C patent/NL300889I2/nl unknown
- 2017-08-08 FR FR17C1028C patent/FR17C1028I2/fr active Active
- 2017-09-06 FI FIEP06712292.9T patent/FI1849470T4/fi active
- 2017-09-07 CY CY2017029C patent/CY2017029I2/el unknown
- 2017-09-07 CY CY20171100947T patent/CY1119393T1/el unknown
- 2017-09-29 LU LU00036C patent/LUC00036I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2630002T5 (es) | Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa | |
| USRE46284E1 (en) | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor | |
| ES2719052T3 (es) | Terapia de combinación con un antibiótico antitumoral | |
| JP2023065622A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| ES2644237T3 (es) | Tratamiento de neurotoxicidad asociada a combinaciones de 5-FU o sus profármacos e inhibidores de DPD | |
| ES2467968T3 (es) | Regímenes de dosificación de un agente antitumoral que comprende un derivado de desoxicitidina | |
| US20150110864A1 (en) | Novel antitumor agent comprising combination of three agents | |
| CN105263499B (zh) | 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合 | |
| ES2348996T3 (es) | Potenciador de radioterapia. | |
| JP5066737B2 (ja) | シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤 | |
| US20060258736A1 (en) | Dosing regimen | |
| JP5581200B2 (ja) | シチジン誘導体及びカルボプラチンを含有する抗腫瘍剤 | |
| WO2006124884A2 (en) | Dosing regimen |